| (V1101) |
Activated platelets bind the pro-atherogenic DNA-binding cytokine HMGB1 via platelet-expressed receptor for advanced glycation end products (RAGE) and toll-like receptor 2 (TLR 2). |
|
I. Ahrens, A. Agrotis, D. Topcic, N. Bassler, Y.-C. Chen, A. Bobik, C. Bode, K. Peter (Freiburg im Breisgau; Melbourne, AU) |
| (V1102) |
Platelet serotonin mediates the efficient recruitment of neutrophils to sites of acute inflammation |
|
D. Dürschmied, G. Suidan, C. Carbo Cots, A. Brill, S. Cifuni, M. Demers, N. Herr, S. Cicko, M. Idzko, C. Bode, D. Wagner (Freiburg im Breisgau; Boston, US) |
| (V1103) |
Interleukin-17 enhances platelet PAR-1-mediated activation of GPIIb/IIIa and increases platelet adhesion on endothelial cells in vitro: implications in vascular inflammation |
|
K. Sopova, C. Erbel, K. Stellos (Frankfurt am Main, Heidelberg) |
| (V1104) |
Interaction of platelets and leukocytes with novel Stent-Polymer Surfaces |
|
S. Rethfeld, S. A. Walz, A. Strohbach, S. B. Felix, R. Busch (Greifswald) |
| (V1105) |
Calpain inhibition improves the diabetes-associated platelet hyper-reactivity |
|
V. Randriamboavonjy, J. Isaak, A. Elgheznawy, I. Fleming (Frankfurt, Frankfurt am Main) |
| (V1106) |
The chaperone cyclophilin A is a Ca2+ regulator in platelets and involved in arterial thrombosis |
|
M. Elvers, P. Seizer, A. Herrmann, P. Münzer, S. Beck, T. Schönberger, O. Borst, F. Lang, M. Gawaz, A. May (Tübingen) |